Gerald M. Lieberman - 01 Jan 2026 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Director
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Issuer symbol
ENTX
Transactions as of
01 Jan 2026
Net transactions value
$0
Form type
4
Filing time
02 Jan 2026, 16:21:15 UTC
Previous filing
09 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LIEBERMAN GERALD M Director KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL /s/ Dana Yaacov-Garbeli, Attorney-in-Fact 02 Jan 2026 0001234346

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Award $0 +38,294 +13% $0.000000 338,454 01 Jan 2026 Direct F1
holding ENTX Ordinary Shares, par value NIS 0.0000769 per share 6,200 01 Jan 2026 By Trust F2
holding ENTX Ordinary Shares, par value NIS 0.0000769 per share 6,200 01 Jan 2026 By Trust F2
holding ENTX Ordinary Shares, par value NIS 0.0000769 per share 6,200 01 Jan 2026 By Trust F2
holding ENTX Ordinary Shares, par value NIS 0.0000769 per share 6,200 01 Jan 2026 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +33,505 $0.000000 33,505 01 Jan 2026 Ordinary Shares, par value NIS 0.0000769 per share 33,505 $1.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.
F2 These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.